Eli Lilly Form 4: Officer increases direct holdings to 137,660.112 shares
Rhea-AI Filing Summary
Daniel Skovronsky, EVP, Chief Scientific Officer and President of LRL & LLY Imm at Eli Lilly & Co (LLY), reported a purchase on 08/12/2025 of 1,000 shares of common stock on Form 4. The transaction is coded P for purchase at a weighted average price of $634.405 with execution prices ranging from $634.21 to $634.42. After the reported purchase the filing shows 137,660.112 shares beneficially owned directly. The filing also discloses indirect holdings of 72,359 shares by a trust, 747 shares by the reporting person’s spouse, and 2,510 shares held in a spousal lifetime access trust transferred on March 10, 2025. The filer disclaims beneficial ownership except to the extent of pecuniary interest.
Positive
- None.
Negative
- None.
Insights
TL;DR Insider purchase of 1,000 shares increases direct holdings modestly; transaction is disclosed at a weighted average price of $634.405.
The Form 4 documents a P purchase of 1,000 shares on 08/12/2025 at a weighted average price of $634.405. Following the purchase the reporting person’s direct beneficial ownership is listed as 137,660.112 shares. The filing itemizes additional indirect holdings by trust and spouse. From a financial-analyst perspective this is a routine officer purchase disclosed under Section 16 and provides transparent detail on price range and holdings; the size of the purchase is small relative to the absolute number of shares reported as owned.
TL;DR Disclosure includes appropriate footnotes and indirect-ownership detail; the Form 4 appears complete and properly executed.
The filing includes clarifying footnotes: a weighted average price range for the purchase, a disclaimer of beneficial ownership except for pecuniary interest, and a note that 2,510 shares were transferred to a spousal lifetime access trust on March 10, 2025. The form is signed by an authorized filer. No derivative transactions are reported. The disclosures address indirect ownership channels and trustee arrangements, consistent with Section 16 reporting expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $634.405 | $634K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $634.21 to $634.42, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. On March 10, 2025, the Reporting Person's spouse transferred 2,510 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and children are beneficiaries.
